# PrognomiQ

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prognomiq

- Industry: Biotechnology
- Headquarters: San Mateo, US
- Website: www.prognomiq.com
- Total disclosed funding: $136M
- Latest round: Series D (Aug 12, 2024)
- Investors on record: 10

## About

PrognomiQ, Inc. is a US-based biotechnology company focused on developing innovative multi-omics platforms for early disease detection and treatment, particularly in complex diseases like cancer.Founded in 2020 in San Mateo, US, PrognomiQ, Inc. is engaged in the development of advanced diagnostic tools. The company has undergone several funding rounds, most recently raising USD 34.32 mn in a Series D round led by Seer, Inc. on August 12, 2024, with participation from notable investors including Bruker Corporation and aMoon. The firm's CEO is Philip Ma, and it was co-founded by Omid Farokhzad.PrognomiQ specializes in developing innovative multi-omics platforms focused on early disease detection and treatment, targeting complex diseases such as cancer. Their core products include proprietary proteomic data generation systems that analyze protein molecules deeply to derive insights into an individual's biological state. This data is integrated with genomic and metabolomic information to create testing products that provide healthcare professionals with actionable insights aimed at improving patient outcomes. Their products are primarily marketed to healthcare institutions, research organizations, and biotechnology firms across North America, Europe, and Asia, emphasizing personalized medicine and advanced diagnostics.PrognomiQ's revenue model is based on the sale of multi-omics testing products and services to healthcare providers and research institutions. The company operates through B2B transactions, forming partnerships with hospitals and clinics utilizing their diagnostic tools. Their transaction structures include direct sales agreements and subscription models for ongoing access to their testing platforms, with flagship products designed to enhance early disease detection capabilities. The pricing reflects the complexity of the analysis provided, catering to the varying needs of their clientele.In August 2024, PrognomiQ, Inc. raised USD 34.32 mn in Series D funding to support the research and development of early detection tests for lung cancer patients. The company plans to expand its product lineup with new testing solutions targeting additional complex diseases, aiming for launches in 2025. Furthermore, PrognomiQ is looking to enter new markets in Asia and Europe by 2025, enhancing its presence in regions where personalized medicine is gaining traction.

## Funding rounds

- Series D, Aug 12, 2024, $34M — Invus [DUP], Bruker Corporation, aMoon, Seer, Inc., Catalio Capital Management
- Series C, Feb 16, 2022, $47M — T Rowe Price, Invus [DUP], Fidelity Investments, Maverick Capital, Wing, Bruker Corporation, aMoon, Emerson Collective, Catalio Capital Management
- Series D, Sep 11, 2020, $55M — Invus [DUP], Fidelity Investments, Maverick Capital, Wing, Bruker Corporation, aMoon, Emerson Collective

## Investors

- Invus [DUP] — Series D, Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series D, Series C
- Maverick Capital (https://capitalatlas.ai/funds/maverick-capital) — Series D, Series C
- Wing (https://capitalatlas.ai/funds/wing) — Series D, Series C
- Bruker Corporation — Series D, Series C
- aMoon (https://capitalatlas.ai/funds/amoon) — Series D, Series C
- Emerson Collective — Series D, Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series C, Series D
- Seer, Inc. — Series D